Cesium-131 Research
With 10+ years of data and a range of studies, over 14,000+ patients have experienced the power of Cesium-131 for treating cancer. Use the catalog of research and data below to learn more about the pioneering research that has been done to help patients around the world.
The Data to Consider When Switching to Cesium-131
Making sound clinical choices based on data is core to us. Our clinical partners say that these core studies can help in the transition to Cesium-131 for prostate cancer treatments.
Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131
Authors: Glaser SM, Chen KS, Benoit RM, Smith RP, Beriwal S.
Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution
Authors: C.S. Platta, D. Khuntia, J. Adkinson, E. Olson, S. Jennifer, H. Odau, R.R. Patel
Dosimetric Evaluation of Permanent Prostate Brachytherapy Using Cs-131 Sources
Authors: Steven Kurtzman, M.D
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer
Authors: Ginsberg RJ, Rubinstein LV
IPSS trends for Cs-131 permanent prostate brachytherapy
Authors: Andrew Jones, Ph.D., Jared Treas, M.S., John Danella, M.D., Omar Yumen, M.D.
IPSS trends for Cs-131 permanent prostate brachytherapy
Authors: Andrew Jones, Ph.D., Jared Treas, M.S., John Danella, M.D., Omar Yumen, M.D.
Surgical Technique and Clinically Relevant Resection Cavity Dynamics Following Implantation of Cesium-131 (Cs-131) Brachytherapy in Patients With Brain Metastases
Authors: Wernicke AG, Lazow SP, Taube S, Yondorf MZ, Kovanlikaya I, Nori D, Christos P, Boockvar JA, Pannullo S, Stieg PE, Schwartz TH
Outpatient Interstitial Implants – Integrating Cesium-131 Permanent Interstitial Brachytherapy into Definitive Treatment for Gynecologic Malignancies
Authors: Jonathan Feddock, MD, Prakash Aryal, PhD, Charles Wooten, MD, Marcus Randall, MD
Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point
Authors: R. Yaparpalvi, J. Rossinow, W.A. Cavanagh, W. Choi, L. Minsky, N. Kahan, W. Bodner, M. Garg, S. Kalnicki, C. Guha
Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point
Authors: R. Yaparpalvi, J. Rossinow, W.A. Cavanagh, W. Choi1, L. Minsky, N. Kahan1, W. Bodner, M. Garg, S. Kalnicki, C. Guha
Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy
Authors: R.M. Benoit, R.P. Smith, S. Beriwal
Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies
Authors: Wooten CE, Randall M, Edwards J, Aryal P, Luo W, Feddock J
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial
Authors: Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE 2nd, Landreneau RJ, Inculet RI, Jones DR, Meyers BF, Harpole DH, Putnam JB Jr, Rusch VW
Permanent interstitial re-irradiation with Au-198 seeds in patients with post-radiation locally recurrent uterine carcinoma
Authors: Kaori Okazawa,* Keiko Yuasa-Nakagawa, Ryo-ichi Yoshimura, and Hitoshi Shibuya
Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma
Chen A, Galloway M, Landreneau R, d’Amato T, Colonias A, Karlovits S, Quinn A, Santucci T, Kalnicki S, Brown D.
The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
Authors: Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V.
Cs-131 Prostate Brachytherapy and Treatment Plan Parameters
Authors: Sutlief S and Wallner K
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
Authors: Amar U. Kishan, MD; Ryan R. Cook, MSPH; Jay P. Ciezki, MD; et al
Cesium131 Prostate Brachytherapy: An early experience
Authors: B. Moran
Point: Cesium-131: Ready for Prime Time
Authors: Bice WS
Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial
Authors: Pham A, Yondorf MZ, Parashar B, Scheff RJ, Pannullo SC, Ramakrishna R, Stieg PE, Schwartz TH5, Wernicke AG
Long-term biochemical outcomes using cesium-131 in prostate brachytherapy.
Authors: Moran BJ, Rice SR, Chhabra AM, Amin N, Braccioforte M, Agarwal M.
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy
Authors: Grimm P1, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, et all.
The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors
Authors: Wernicke AG, Yondorf MZ, Parashar B, Nori D, Clifford Chao KS, Boockvar JA, Pannullo S, Stieg P, Schwartz TH
Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy
Authors: J.S. Musmacher, R.T. Byrnes, M. Ghaly, K. Satchwill, L. Rumpf
Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases
Authors: Wernicke AG, Yondorf MZ, Peng L, Trichter S, Nedialkova L, Sabbas A, Kulidzhanov F, Parashar B, Nori D, Clifford Chao KS, Christos P, Kovanlikaya I, Pannullo S, Boockvar JA, Stieg PE, Schwartz TH.
Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy
Authors: J.S. Musmacher, R.T. Byrnes, M. Ghaly, K. Satchwill, L. Rumpf
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
W. James Morris, MD, FRCPC, W. James Morris MD, FRCPC, Scott Tyldesley, MD, FRCPC, …
Is there Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Radioisotope?
Authors: S.G. DeFoe, S. Beriwal, R. Smith, R. Benoit
